Edgen Stock·Mar 31 2026, 16:03Key Takeaways:
Eli Lilly and Co ($LLY) will acquire Centessa Pharmaceuticals ($CNTA) for approximately $6.3 billion in cash, a move designed to add a key sleep-wake disorder asset to its neuroscience pipeline.
The deal, announced Tuesday, values Centessa at $38 per share. The terms also include a potential contingent value right (CVR) of up to $9 per share, which could bring the total transaction value to $7.8 billion if certain milestones are met.
The acquisition gives Eli Lilly control of Centessa's lead asset, cleminorexton, which is being developed for narcolepsy and other sleep-wake disorders. This strategic purchase significantly expands Lilly's portfolio in the neuroscience sector, a key area of growth for the pharmaceutical giant.
For Centessa shareholders, the upfront cash offer represents a significant premium. The deal is expected to cause a surge in Centessa's stock price. For Eli Lilly, the investment is a long-term strategic play to strengthen its position in the competitive neuroscience market.
The acquisition highlights a continuing trend of consolidation within the pharmaceutical industry, as large companies seek to replenish their pipelines by acquiring smaller firms with promising assets. Investors will be watching for the successful integration of cleminorexton into Lilly's development program, with future trial data being the next key catalyst.
This article is for informational purposes only and does not constitute investment advice.
